| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | DRUG | Common Shares | Purchase | $1.08M | +238K | +52.63% | $4.53 | 691K | Oct 15, 2024 | See Footnote | F1, F2 |
| transaction | DRUG | Common Shares | Purchase | $374K | +63.2K | +9.15% | $5.92 | 754K | Oct 15, 2024 | See Footnote | F2, F3 |
| transaction | DRUG | Common Shares | Purchase | $214K | +33.3K | +4.42% | $6.42 | 787K | Oct 15, 2024 | See Footnote | F2, F4 |
| transaction | DRUG | Common Shares | Purchase | $65K | +8.9K | +1.13% | $7.31 | 796K | Oct 15, 2024 | See Footnote | F2, F5 |
| transaction | DRUG | Common Shares | Purchase | $22.9K | +2.6K | +0.33% | $8.80 | 799K | Oct 15, 2024 | See Footnote | F2, F6 |
| transaction | DRUG | Common Shares | Purchase | $25K | +2.7K | +0.34% | $9.26 | 801K | Oct 15, 2024 | See Footnote | F2, F7 |
| transaction | DRUG | Common Shares | Purchase | $225K | +19.2K | +2.39% | $11.72 | 820K | Oct 15, 2024 | See Footnote | F2, F8 |
| transaction | DRUG | Common Shares | Purchase | $56.9K | +4.61K | +0.56% | $12.35 | 825K | Oct 15, 2024 | See Footnote | F2, F9 |
| transaction | DRUG | Common Shares | Purchase | $923K | +39.7K | +4.82% | $23.22 | 865K | Oct 16, 2024 | See Footnote | F2, F10 |
| transaction | DRUG | Common Shares | Purchase | $172K | +7.15K | +0.83% | $24.03 | 872K | Oct 16, 2024 | See Footnote | F2, F11 |
| transaction | DRUG | Common Shares | Purchase | $78.4K | +3.11K | +0.36% | $25.22 | 875K | Oct 16, 2024 | See Footnote | F2, F12 |
| Id | Content |
|---|---|
| F1 | Represents the weighted average sale price of common shares purchased in a series of open market transactions on the transaction date at prices ranging from $4.16 to $4.89 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission (the "SEC"), the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund (as defined below). |
| F2 | Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as general partner of the Master Fund. Bihua Chen serves as the managing member of GP LLC and the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose. |
| F3 | Represents the weighted average sale price of common shares purchased in a series of open market transactions on the transaction date at prices ranging from $5.42 to $6.15 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund. |
| F4 | Represents the weighted average sale price of common shares purchased in a series of open market transactions on the transaction date at prices ranging from $6.16 to $7.12 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund. |
| F5 | Represents the weighted average sale price of common shares purchased in a series of open market transactions on the transaction date at prices ranging from $7.28 to $7.59 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund. |
| F6 | Represents the weighted average sale price of common shares purchased in a series of open market transactions on the transaction date at prices ranging from $8.80 to $8.905 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund. |
| F7 | Represents the weighted average sale price of common shares purchased in a series of open market transactions on the transaction date at prices ranging from $9.26 to $9.31 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund. |
| F8 | Represents the weighted average sale price of common shares purchased in a series of open market transactions on the transaction date at prices ranging from $11.18 to $12.125 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund. |
| F9 | Represents the weighted average sale price of common shares purchased in a series of open market transactions on the transaction date at prices ranging from $12.16 to $12.50 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund. |
| F10 | Represents the weighted average sale price of common shares purchased in a series of open market transactions on the transaction date at prices ranging from $22.76 to $23.73 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund. |
| F11 | Represents the weighted average sale price of common shares purchased in a series of open market transactions on the transaction date at prices ranging from $23.775 to $24.74 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund. |
| F12 | Represents the weighted average sale price of common shares purchased in a series of open market transactions on the transaction date at prices ranging from $24.78 to $25.705 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of these shares were purchased by the Master Fund. |